PROTECTOR STUDY HOLDS FIRST COLLABORATORS’ MEETING
A successful first meeting of the PROTECTOR study collaborators has been held, under the guidance of Chief Investigator Professor Ranjit Manchanda and his team at the Wolfson Institute.
9 March 2020
The PROTECTOR research study offers women who are at increased risk of ovarian cancer a new two-step option, of early salpingectomy and delayed oophorectomy, to prevent ovarian cancer. The study will assess women’s views and the impact of this approach on sexual function, hormone levels, quality of life and overall satisfaction, and will compare these outcomes with well-being in women undergoing the traditional approach of removal of both tubes and ovaries at the same operation, and also women who do not undergo surgery. This national study aims to recruit 1000 women, 333 in each of the three study arms, and has 28 active sites, with 10 further sites in the activation process. Participants will be followed up for three years.
PROTECTOR is the only ovarian cancer surgical prevention study and, in fact, the only gynaecological oncology surgical study, being conducted in the UK. Women may be eligible to take part if they are at increased risk of ovarian cancer (either because they carry a BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 faulty gene, or have a strong family history of ovarian cancer), are aged over 30 and have not gone through the menopause, and have completed their family. Eligible women will be given the choice of choosing which of the three arms of the study they wish to join – the two staged operation (initial removal of tubes followed by later removal of ovaries at a second operation), the current standard NHS operation which removes both tubes and ovaries at the same time, or as a control (no operation). Further information is available on the PROTECTOR Study website: http://protector.org.uk/